alexa A New Treatment Choice against Multi-Drug Resistant Pse
ISSN: 2155-9597

Journal of Bacteriology & Parasitology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

A New Treatment Choice against Multi-Drug Resistant Pseudomonas aeruginosa: Doripenem

Carolina Chaparro Barrios1, Lucía Ciancotti-Oliver1, Daniel Bautista-Rentero1*, Carlos Adán-Tomás2 and Vicente Zanón-Viguer1

1Preventive Medicine Department, Hospital Dr. Peset, Valencia, Spain

2Pharmacy Department, Hospital Dr. Peset, Valencia, Spain

*Corresponding Author:
Daniel Bautista-Rentero
Preventive Medicine Department
Hospital Dr. Peset, Valencia, Spain
Tel: 34687914499
Fax: 34961622704
E-mail: [email protected]

Received date: April 08, 2014; Accepted date: September 19, 2014; Published date: September 23, 2014

Citation: Barrios CC, Ciancotti-Oliver L, Bautista-Rentero D, Adán-Tomás C, Zanón-Viguer V (2014) A New Treatment Choice against Multi-Drug Resistant Pseudomonas aeruginosa: Doripenem. J Bacteriol Parasitol 5:199. doi: 10.4172/2155-9597.1000199

Copyright: © 2014 Barrios CC, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Pseudomonas aeruginosa is a Gram-negative strict aerobic Bacillus that causes around 10% of nosocomial infections. This bacillus can become resistant to multiple antibiotics, and it has been described mainly in inmuno compromised patients. The prevalence of multidrug resistant Pseudomonas has been increasing over the last few years. Currently we have new agents to treat this type of infection. Doripenem is the new B-lactam from the carbapenem family, which has demonstrated in vitro the best activity against multidrug resistant Pseudomonas aeruginosa in different studies. Its mechanism of action consists of the inactivation of penicillin-binding proteins in the cell wall. This agent has been indicated in the treatment of several infections, such as complicated intraabdominal infections, complicated urinary tract infections and nosocomial pneumonia. The principal difference between doripenem and the other carbapenems, is the capacity of preventing the generation of resistant strains of Pseudomonas aeruginosa, so it is especially useful for severe infections caused by multidrug resistant Pseudomonas aeruginosa. But this situation may change if we don't use antibiotics properly. Promoting rationale use of antibiotics to treat infections caused by Pseudomonas aeruginosa may be critical to make the emergence of multidrug resistant strains difficult. The present review describes the main features of doripenem and its potential role in managing infections due to multi-drug resistant Pseudomonas aeruginosa.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version